• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

循环miR144 - 3p和miR190a - 5p作为甲状腺结节分化有前景的诊断生物标志物对临床实践的意义

The Implications for Clinical Practice of Circulating miR144-3p and miR190a-5p as Promising Diagnostic Biomarkers for Thyroid Nodule Differentiation.

作者信息

Hassan Basima, Omran Mohamed M, Youssef Magdy M, Refaat Manar, Abouzid Amr, Abdel Wahab Abdel Hady A, Bakr Yasser M

机构信息

Biochemistry Division, Chemistry Department, Faculty of Science, Mansoura University, Mansoura, Egypt.

Chemistry Department, Faculty of Science, Helwan University, Cairo, Egypt.

出版信息

Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241291637. doi: 10.1177/15330338241291637.

DOI:10.1177/15330338241291637
PMID:39703128
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11662322/
Abstract

BACKGROUND AND AIMS

Thyroid cancer, a prevalent endocrine malignancy, often presents as thyroid nodules, whose benign or malignant nature is challenging to determine. This study aims to identify circulating miRNA panels that may distinguish between benign nodules, papillary thyroid cancer, and normal thyroid conditions, building on extensive research into miRNAs as potential thyroid cancer biomarkers.

MATERIALS AND METHODS

As a cross-sectional case-control study the study revealed the quantification of the 17-miRNA panel was evaluated using qRT-PCR method on 60 blood samples, comprising 25 patients diagnosed with PTC, 24 patients with benign lesions, and 11 healthy controls.

RESULTS

We found that seven miRNAs, including miR144-3p and miR190a-5p, exhibited statistically significant variations in their expression levels, and miR144-3p exhibited the most superior diagnostic capability in distinguishing between malignant and healthy groups, as well as between benign and healthy groups. The concurrent utilization of miR144-3p, miR148a-3p, and miR190a-5p resulted in an enhancement of sensitivity from 76% to 88%.

CONCLUSION

Our study suggests that miR144-3p and miR190a-5p exhibit potential as biomarkers for distinguishing between benign and malignant thyroid nodules and healthy individuals, and further investigation is necessary to evaluate their clinical significance.

摘要

背景与目的

甲状腺癌是一种常见的内分泌恶性肿瘤,常表现为甲状腺结节,其良恶性难以确定。本研究旨在基于对作为潜在甲状腺癌生物标志物的微小RNA(miRNA)的广泛研究,确定可区分良性结节、甲状腺乳头状癌和正常甲状腺状态的循环miRNA组合。

材料与方法

作为一项横断面病例对照研究,该研究使用qRT-PCR方法对60份血样中的17-miRNA组合进行定量评估,这些血样包括25例诊断为甲状腺乳头状癌(PTC)的患者、24例良性病变患者和11例健康对照。

结果

我们发现包括miR144-3p和miR190a-5p在内的7种miRNA在表达水平上表现出统计学上的显著差异,且miR144-3p在区分恶性与健康组以及良性与健康组方面表现出最优异的诊断能力。同时使用miR144-3p、miR148a-3p和miR190a-5p可使灵敏度从76%提高到88%。

结论

我们的研究表明,miR144-3p和miR190a-5p具有作为区分良性和恶性甲状腺结节以及健康个体的生物标志物的潜力,有必要进一步研究以评估它们的临床意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b1/11662322/c8e90b40b07a/10.1177_15330338241291637-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b1/11662322/2e84f6462641/10.1177_15330338241291637-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b1/11662322/aad79531cb76/10.1177_15330338241291637-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b1/11662322/c8e90b40b07a/10.1177_15330338241291637-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b1/11662322/2e84f6462641/10.1177_15330338241291637-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b1/11662322/aad79531cb76/10.1177_15330338241291637-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b1/11662322/c8e90b40b07a/10.1177_15330338241291637-fig3.jpg

相似文献

1
The Implications for Clinical Practice of Circulating miR144-3p and miR190a-5p as Promising Diagnostic Biomarkers for Thyroid Nodule Differentiation.循环miR144 - 3p和miR190a - 5p作为甲状腺结节分化有前景的诊断生物标志物对临床实践的意义
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241291637. doi: 10.1177/15330338241291637.
2
Differential expression of cytokines and vitamin D in benign and malignant thyroid diseases.细胞因子和维生素D在甲状腺良恶性疾病中的差异表达
Sci Rep. 2025 Jul 2;15(1):23493. doi: 10.1038/s41598-025-06882-1.
3
Circulating microRNA124-3p, microRNA9-3p and microRNA196b-5p may be potential signatures for differential diagnosis of thyroid nodules.循环中的微小RNA124-3p、微小RNA9-3p和微小RNA196b-5p可能是甲状腺结节鉴别诊断的潜在标志物。
Oncotarget. 2016 Dec 20;7(51):84165-84177. doi: 10.18632/oncotarget.12389.
4
Altered Serum MicroRNA Profile May Serve as an Auxiliary Tool for Discriminating Aggressive Thyroid Carcinoma from Nonaggressive Thyroid Cancer and Benign Thyroid Nodules.血清中 microRNA 谱的改变可作为辅助工具,用于鉴别侵袭性甲状腺癌与非侵袭性甲状腺癌和良性甲状腺结节。
Dis Markers. 2019 Sep 16;2019:3717683. doi: 10.1155/2019/3717683. eCollection 2019.
5
Multi-Omics-Based Characterization of DNA Methylation Episignatures for Papillary Thyroid Cancer in a Chinese Population.基于多组学的中国人群甲状腺乳头状癌DNA甲基化表型特征分析
Thyroid. 2025 May 30. doi: 10.1089/thy.2024.0611.
6
Exosomal miRNAs are potential diagnostic biomarkers between malignant and benign thyroid nodules based on next-generation sequencing.基于下一代测序的细胞外体 miRNA 是良恶性甲状腺结节之间潜在的诊断生物标志物。
Carcinogenesis. 2020 Mar 13;41(1):18-24. doi: 10.1093/carcin/bgz160.
7
RASGEF1C methylation for the distinguishment and classification of benign and malignant thyroid tumors.用于鉴别和分类甲状腺良恶性肿瘤的RASGEF1C甲基化
Clin Epigenetics. 2025 Jul 14;17(1):124. doi: 10.1186/s13148-025-01931-y.
8
Challenges in circulating miRNA analysis in adrenocortical tumors.肾上腺皮质肿瘤循环miRNA分析中的挑战
Endocr Relat Cancer. 2025 Jun 17;32(6). doi: 10.1530/ERC-25-0045. Print 2025 Jun 1.
9
Circulating microRNAs and Clinicopathological Findings of Papillary Thyroid Cancer: A Systematic Review.循环 microRNAs 与甲状腺乳头状癌的临床病理特征:系统评价。
In Vivo. 2022 Jul-Aug;36(4):1551-1569. doi: 10.21873/invivo.12866.
10
Diagnostic and Prognostic Potential of Circulating miR-1301-3p, miR-106a-5p, miR-129-5p, miR-3613-3p, and miR-647 microRNAs in Gastric Cancer.循环miR-1301-3p、miR-106a-5p、miR-129-5p、miR-3613-3p和miR-647微小RNA在胃癌中的诊断和预后潜力
Biochemistry (Mosc). 2025 Jun;90(6):671-682. doi: 10.1134/S000629792460385X.

本文引用的文献

1
NR2F1-AS1/miR-190a/PHLDB2 Induces the Epithelial-Mesenchymal Transformation Process in Gastric Cancer by Promoting Phosphorylation of AKT3.NR2F1-AS1/miR-190a/PHLDB2通过促进AKT3磷酸化诱导胃癌上皮-间质转化过程
Front Cell Dev Biol. 2021 Oct 22;9:688949. doi: 10.3389/fcell.2021.688949. eCollection 2021.
2
The upregulation of oncogenic miRNAs in swabbed samples obtained from oral premalignant and malignant lesions.从口腔癌前病变和恶性病变的拭子样本中上调的致癌 miRNA。
Clin Oral Investig. 2022 Feb;26(2):1343-1351. doi: 10.1007/s00784-021-04108-y. Epub 2021 Aug 3.
3
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
4
CircRNA_104565 Promoted Cell Proliferation in Papillary Thyroid Carcinoma by Sponging miR-134.环状RNA_104565通过吸附miR-134促进甲状腺乳头状癌细胞增殖。
Int J Gen Med. 2021 Jan 18;14:179-185. doi: 10.2147/IJGM.S288360. eCollection 2021.
5
MicroRNA Deregulation in Papillary Thyroid Cancer and its Relationship With BRAF V600E Mutation.甲状腺乳头癌中 microRNA 的失调及其与 BRAF V600E 突变的关系。
In Vivo. 2021 Jan-Feb;35(1):319-323. doi: 10.21873/invivo.12262.
6
Epigenetic Field Cancerization in Gastric Cancer: microRNAs as Promising Biomarkers.胃癌中的表观遗传场致癌作用:微小RNA作为有前景的生物标志物
J Cancer. 2019 Feb 26;10(6):1560-1569. doi: 10.7150/jca.27457. eCollection 2019.
7
Cancer statistics, 2019.癌症统计数据,2019 年。
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
8
Identifying the Best Marker Combination in CEA, CA125, CY211, NSE, and SCC for Lung Cancer Screening by Combining ROC Curve and Logistic Regression Analyses: Is It Feasible?通过 ROC 曲线和逻辑回归分析联合确定 CEA、CA125、CY211、NSE 和 SCC 在肺癌筛查中的最佳标志物组合:是否可行?
Dis Markers. 2018 Oct 1;2018:2082840. doi: 10.1155/2018/2082840. eCollection 2018.
9
MicroRNA-144 inhibits proliferation by targeting WW domain-containing transcription regulator protein 1 in papillary thyroid cancer.微小RNA-144通过靶向乳头状甲状腺癌中含WW结构域的转录调节蛋白1来抑制细胞增殖。
Oncol Lett. 2018 Jan;15(1):1007-1013. doi: 10.3892/ol.2017.7440. Epub 2017 Nov 17.
10
Downregulation of cyclin-dependent kinase 8 by microRNA-148a suppresses proliferation and invasiveness of papillary thyroid carcinomas.微小RNA-148a对细胞周期蛋白依赖性激酶8的下调抑制甲状腺乳头状癌的增殖和侵袭性。
Am J Cancer Res. 2017 Oct 1;7(10):2081-2090. eCollection 2017.